Introduction
The topic assigned to me was phrased in the form of a question that read, "How should the MTD be selected for chronic bioassays?" As a prelude, the response to the question warrants a brief review of the historical evolution of this issue. Table 1 is a summary of the historical chronology by which the dose selection process has evolved over the past 30 years. In the early to mid-1950s, the major emphasis was in the evaluation of chronic organ toxicity rather than carcinogenicity, and estimates of potential human exposure were factored into the dose selection process for the animal studies. In the early to mid-1960s, the emphasis shifted to the use. of exaggerated (sometimes lethal) doses for the purpose of a short-term qualitative screening evaluation of carcinogenicity potential. This time period was characterized by the use of a relatively crude basis for dose selection, with the emphasis on mortality and frank body weight loss. In the early to mid-1970s, the availability of laboratory animals with better survival led to the lengthening of the duration of dosing with the maximal dose levels compatible with survival of a sufficient number of animals. This time period saw some slight improvements in the relatively crude basis for dose selection.
In the early to mid-1980s, there was a carryover of some of the previous philosophy, but with a recognition of the need for a more scientifically valid basis for dose selection. This time period has been characterized by the need for (a) more definitive subchronic studies, (b) definition and recognition of the critical role played by dose-related changes in kinetics, and (c) the recognition of the need to avoid dose levels that create nonphysiological conditions of treatment. Thus, it is apparent that this issue of dose selection for chronic toxicity and oncogenicity studies has been and continues to be a topic of debate and controversy. I believe this issue of dose selections remains the most challenging aspect of study design, and its importance is underscored by the current *Mammalian and Environmental Toxicology, The Dow Chemical Company, Midland, MI 48674. format of addressing both chronic toxicity and oncogenicity potential in one and the same joint study. Based on the consideration of the extensive human and physical resources that must be appropriated for the conduct of these long-term toxicity studies, it is imperative that we strive to maximize the yield from these efforts by conducting the most scientifically sound type of studies specifically designed to jointly address both chronic toxicity and oncogenicity. The subsequent interpretation of the study results is also greatly facilitated by the use of an optimal joint study design wherein it is more feasible to evaluate any possible mechanistic relationships between chronic toxicity and observed oncogenic responses. Based on these factors, it is recommended that future study designs continue to jointly address both chronic toxicity and oncogenic potential. There is considerable merit in restating the basic premise and rationale that serves as the driving force to warrant the conduct of these studies. Simply stated, these long-term animal studies are conducted to generate both qualitative and quantitative dose-response data that are useful via extrapolation to the evaluation of potential human risk associated with known or anticipated level(s) of exposure by humans. As stated, this definition of the basic rationale stresses not only the qualitative and quantitative aspects of the animal doseresponse data, but also the known or anticipated levels of exposure by humans. Figure 1 graphically depicts the spectrum of biologic responses typically defined in a subchronic or chronic animal toxicity study. The spectrum ofbiologic response typically spans a graded series of increasing dose levels that ranges from a lower dose level at which no response is elicited (the No-Observed-Effect-Level, or NOEL), to a slightly higher dose level at which we may observe an adaptive physiologic response (the No-Observed-Adverse-Effect-Level, or NOAEL), to increasingly higher dose levels that will define the Lowest-Observed-Effect-Level (LOEL) and also the Frank-Effect-Level (FEL). As depicted in the lower portion of Figure 1 , the high dose selected for the chronic toxicity study typically represents a point selected along the range of those dose levels extending from LOEL-LOAEL-FEL. The specific points along this spectrum that will be selected as the high-dose level remains a point of controversy and debate among toxicologists and pathologists. Some scientists recommend selection of a maximally tolerated dose or MTD that is in the range of the FEL, based on the premise that the principal limiting factor should be based on Table 2 lists the perceived advantages and disadvantages currently associated with the selection of maximal tolerated doses for chronic animal bioassays. Proponents of high-dose testing use the primary argument that these bioassays are relatively insensitive for detecting carcinogenic effects. Other scientists express concern over the disadvantages of MTD testing, such as metabolic overload and lack of relevance for safety assessment of human exposure. Table 3 depicts the key factors that are recommended as the basis for my response to the question of highdose selection for chronic animal bioassays. Conceptually, it is imperative that the discipline of toxicology strive to utilize the best available technology of the 1980s for high-dose selection. Operationally, this wili require that the parameters evaluated in the subchronic (and chronic) dose-response studies must be sufficiently comprehensive to supplement the relatively crude parameters used historically in high-dose selection. Based on conventional clinical and morphologic parameters, the high dose level selected for the chronic studies (3) . "To slavishly endorse the MTD is to ignore the only purpose of the study: develop some understanding of risk/benefit at real exposure limits" (4) . "The use of the MTD is an anachronism" (4). "The MTD might be an excessive multitude of the human exposure.
We have examples where the MTD is 30,000 x the human exposure" (4). "Nonsensical academic exercise... ... Tumors (or anything else) observed at these doses are essentially irrelevant to safety considerations for man" (5). should represent that dose level which elicited some discernible but slight degree of toxicity in the subchronic studies. Good science (and humane reasons) dictates against the selection of higher dose levels for the chronic studies that exceed that dose level which in the subehronic studies has elicited a discernible but slight degree of toxicity.
We must also prospectively conduct sufficient metabolism and kinetic studies that allow selection of highdose levels that are (a) within the range of linear doseresponse kinetics, and (b) avoid metabolic overdosing. Finally, we must factor in the data on the known or anticipated levels of human exposure associated with the substance. It is only through the use of these recommendations that the discipline of toxicology can profess to be applying the best available technology of the 1980s to the issue at hand, namely, selection of highdose levels that are scientifically appropriate and useful for the subsequent extrapolation to That's what I wanted to go to. As Dr. Albert pointed out, the two purposes are to test whether there's potential of a chemical to be a carcinogen at whatever dose, and extrapolation to low doses. Let's forget about the species extrapolation. I don't care how you set up the dose response; if all you do is count tumors, you'll never do low-dose extrapolation by just counting tumors on the animal. I mean, I think NCTR's EDLI study proves that point. How many chemicals could you test 50,000 animals with? So the only way that I think you're going to scientifically extrapolate to low doses is by incorporating the mechanisms that we know about-at least some of the steps we have pretty well defined. You have to take these into account.
Looking at promutagenic lesions, you can go down to doses to which humans are exposed. I think that should be the approach rather than trying to design tumor studies to get down to human exposure doses. I don't think it's possible. DR Tying this back to Ray's final point, are there secondclass citizens? I don't think that he can say that nongenotoxic carcinogens per se are less dangerous. Because there's TCDD and many others. However, if you put two parameters together, if you say it's a nongenotoxic carcinogen and it required greater than 1000 mg/ kg/day to produce the tumor, then maybe you have a candidate for some second-class citizens. That is to say, chemicals which require less of our attention than maybe some of the others.
DR. MICHAEL DIETER, NIEHS: As one of the chemical managers involved in this program in selecting these doses and trying to carry out these tests, I'd like to make the remark that the other side is also valid. Just as in the genotoxic tests, one of the things that should be avoided is a possibility of a false negative. Just as the example you cited, the chemical was used in very high doses. There's another example that could be cited just as well on the other side of the coin where the chemical was tested in the tenths of parts per million range and found to be completely negative in a 2-year test. And when tested at tens or hundreds of milligrams per kilogram in another test it was found to be carcinogenic, causing multiple tumors in both sexes and both species.
If you look at a scenario of this sort by selecting a dose level, the highest of which only caused some sensitivity responses in the treated animals in the prechronic studies, you would have entirely missed a carcinogenic response by not selecting higher doses. UNKNOWN SPEAKER: Let me respond. Don't get me wrong. If you are dealing with tens of milligrams per kilogram per day, surely you must deal with the issues the way we have been dealing with them. I agree with you. I'm talking about that set that's way over there where you need over 1000 mg/kg/day. And then I challenge you to show me that we're dealing with the real problem.
So it's not the ones that are in the range of, say, less than a thousand. It's the ones greater than a thousand where I think we're losing credibility and we're wasting resources.
DR. KOcIBA: Dr. Albert has motioned that we must move on to the next paper. I want to thank everybody for participating. I'm sure we could go on for 3 hr on this issue.
